Pharmaceutical composition for prevention or treatment of fibrotic diseases and application thereof

A technology of fibrotic diseases and compositions, applied in the field of medicine, can solve problems such as organ function decline and organ fibrosis, and achieve good prevention and treatment effects
CN107019697AInactive Publication Date: 2017-08-08REYOUNG SUZHOU BIOLOGY SCI & TECH CO LTD
3 Cites 31 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
REYOUNG SUZHOU BIOLOGY SCI & TECH CO LTD
Publication Date
2017-08-08
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention discloses application of nintedanib, its salt and solvate in preparation of drugs for prevention or treatment of fibrotic diseases and a pharmaceutical composition for prevention or treatment of fibrotic diseases. The pharmaceutical composition comprises an active component and excipients, wherein the active component is selected from one or more of nintedanib, its salt and solvate. The nintedanib preparation provided by the invention can achieve treatment or prevention of fibrotic diseases on VEGF, PDGF and FGF angiogenesis receptors, and can provide an effective drug concentration, thus reaching a good control effect.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention belongs to the field of medicine, and in particular relates to a pharmaceutical composition for preventing or treating fibrosis diseases and its application. Background technique

[0002] Nintedanib, namely 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino) -1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone, molecular formula C31H33N5O4, the compound structure is as follows:

[0003]

[0004] Nintedanib is a novel angiogenesis inhibitor that can simultaneously act on three key receptor families involved in angiogenesis: vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR) ) and fibroblast growth factor receptor (FGFR). Nintedanib has been approved by the FDA and EMA for the treatment of idiopathic pulmonary fibrosis (IPF), and has also been approved by the EMA for use in combination with docetaxel after first-line chemotherapy for locally advanced adenocar...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More